These results demonstrate that IRAK1 promotes the survival of HNSCC cells and that IRAK1 inhibition may be a novel therapeutic strategy to enhance cell death in this tumor type. This evidence concerns the gene IRAK1 and head and neck squamous cell carcinoma.